Eli Lilly and Co
Viking Therapeutics stock jumps 80% after positive weight loss drug trial results
Cr | Istock | Getty Images Shares of Viking Therapeutics soared more than 80% in premarket trading Tuesday after the company’s experimental weight loss drug showed promising initial results in a mid-stage trial. Viking Therapeutics is one of several small obesity drugmakers hoping to enter the budding weight loss drug industry, which analysts say could […]
Read More
New sickle cell gene therapies are a breakthrough, but solving how to pay their high prices is a struggle
Blood sample of patient positive tested for sickle cell. Kitsawet Saethao | Istock | Getty Images The approval of two gene therapies to treat sickle cell disease has given hope to patients who suffer from the debilitating disease, which overwhelmingly affects Black people and people of color. Health officials now face a challenge in finding […]
Read More
Pharma and journey-share vendors are among most overbought S&P 500 shares this 7 days
A group of effectively-identified shares together with some market titans could be in for a correction following acquiring snatched up throughout this week’s choppy buying and selling. The S & P 500 and Dow Jones Industrial Typical have been on keep track of midday Friday to write-up compact gains on the 7 days, and the […]
Read More
Most employer health plans don't cover new blockbuster weight loss drugs, but that's going to change
Many U.S. companies are grappling with health insurance coverage issues for workers when it comes to GLP-1 drugs for weight loss. Despite the hefty price tag — typically between $1,000 to $1,500 a month — consumers are clamoring for drugs like Novo Nordisk‘s Wegovy and Eli Lilly‘s Zepbound. This class of drugs, historically used to […]
Read More
In this fast-paced bull market, we're increasing our Club price targets on 4 stocks
It’s been hard to keep up. That’s the story of the big stock winners this year. They just keep winning and winning and winning. For analysts on Wall Street and here at the Club, it seems like some of these names are smashing through our six-to-nine-month price targets every few weeks. To that end, we’re […]
Read More
What Eli Lilly investors can learn from the slow launch of a competitor's drug
Club holding Eli Lilly is expecting to get approval for its Alzheimer’s treatment in the coming weeks, but investors looking for immediate financial success should temper their expectations. On its fourth-quarter earnings call Tuesday, rival drugmaker Biogen shared data that showed its therapy for the memory-robbing disease, Leqembi, is off to a slower-than-expected start. In […]
Read More
Here's why we would be considering buying more Eli Lilly shares if they were down Tuesday
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Tuesday’s key moments. 1. U.S. stocks tumbled Tuesday on hotter-than-expected retail inflation data. The surprise uptick in the January consumer price index sent bond yields higher and the Dow , the S & […]
Read More
Federal judge tosses lobbying group's lawsuit challenging Medicare drug price negotiations
Activists protest the price of prescription drug costs in front of the U.S. Department of Health and Human Services (HHS) building on October 06, 2022 in Washington, DC. Anna Moneymaker | Getty Images A federal judge on Monday tossed a lawsuit brought by a major pharmaceutical industry lobbying group and two other organizations, which challenged […]
Read More
Weight loss drugs are still hard to find — but Novo Nordisk and Eli Lilly are trying to change that
Injection pens of Novo Nordisk’s weight-loss drug Wegovy are shown in this photo illustration in Oslo, Norway, Nov. 21, 2023. Victoria Klesty | Reuters The insatiable demand for weight loss drugs is trouncing supply, leaving many patients struggling to find the injectable treatments. The dominant weight loss drugmakers, Novo Nordisk and Eli Lilly, have said […]
Read More
Wall Street gives 2 of our healthcare stocks well-deserved price target bumps
Wall Street liked what it saw from GE Healthcare and Eli Lilly in their earnings reports, leading to a round of well-deserved price target bumps for the Club stocks. Analysts at four equity research firms boosted their price targets for GE Healthcare since the maker of MRI machines and other medical equipment on Tuesday delivered […]
Read More